ArticleTrials2025

A phase II, randomized, open-labeled study to evaluate low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer (TNBC).

Adhip Arora et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.